Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

A novel oncogenic role for urokinase receptor in leukemia cells: molecular sponge for oncosuppressor microRNAs.

Li Santi A, Gorrasi A, Alfieri M, Montuori N, Ragno P.

Oncotarget. 2018 Jun 12;9(45):27823-27834. doi: 10.18632/oncotarget.25597. eCollection 2018 Jun 12.

2.

N-Formyl Peptide Receptors Induce Radical Oxygen Production in Fibroblasts Derived From Systemic Sclerosis by Interacting With a Cleaved Form of Urokinase Receptor.

Napolitano F, Rossi FW, Pesapane A, Varricchio S, Ilardi G, Mascolo M, Staibano S, Lavecchia A, Ragno P, Selleri C, Marone G, Matucci-Cerinic M, de Paulis A, Montuori N.

Front Immunol. 2018 Apr 4;9:574. doi: 10.3389/fimmu.2018.00574. eCollection 2018.

3.

Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors.

Mauro CD, Pesapane A, Formisano L, Rosa R, D'Amato V, Ciciola P, Servetto A, Marciano R, Orsini RC, Monteleone F, Zambrano N, Fontanini G, Servadio A, Pignataro G, Grumetto L, Lavecchia A, Bruzzese D, Iaccarino A, Troncone G, Veneziani BM, Montuori N, Placido S, Bianco R.

Sci Rep. 2017 Aug 24;7(1):9388. doi: 10.1038/s41598-017-10062-1.

4.

Recent Advances in the Function of the 67 kDa Laminin Receptor and its Targeting for Personalized Therapy in Cancer.

Pesapane A, Ragno P, Selleri C, Montuori N.

Curr Pharm Des. 2017;23(32):4745-4757. doi: 10.2174/1381612823666170710125332.

PMID:
28699539
5.

The Urokinase/Urokinase Receptor System in Mast Cells: Effects of its Functional Interaction with fMLF Receptors.

Rossi FW, Prevete N, Rivellese F, Napolitano F, Montuori N, Postiglione L, Selleri C, de Paulis A.

Transl Med UniSa. 2016 Nov 1;15:34-41. eCollection 2016 Nov.

6.

Urokinase type plasminogen activator receptor (uPAR) as a new therapeutic target in cancer.

Montuori N, Pesapane A, Rossi FW, Giudice V, De Paulis A, Selleri C, Ragno P.

Transl Med UniSa. 2016 Nov 1;15:15-21. eCollection 2016 Nov.

7.

67 kDa laminin receptor (67LR) in normal and neoplastic hematopoietic cells: is its targeting a feasible approach?

Montuori N, Pesapane A, Giudice V, Serio B, Rossi FW, De Paulis A, Selleri C.

Transl Med UniSa. 2016 Nov 1;15:8-14. eCollection 2016 Nov.

8.

Everolimus induces Met inactivation by disrupting the FKBP12/Met complex.

Raimondo L, D'Amato V, Servetto A, Rosa R, Marciano R, Formisano L, Di Mauro C, Orsini RC, Cascetta P, Ciciola P, De Maio AP, Di Renzo MF, Cosconati S, Bruno A, Randazzo A, Napolitano F, Montuori N, Veneziani BM, De Placido S, Bianco R.

Oncotarget. 2016 Jun 28;7(26):40073-40084. doi: 10.18632/oncotarget.9484.

9.

Involvement of urokinase receptor in the cross-talk between human hematopoietic stem cells and bone marrow microenvironment.

Selleri C, Montuori N, Salvati A, Serio B, Pesapane A, Ricci P, Gorrasi A, Li Santi A, Hoyer-Hansen G, Ragno P.

Oncotarget. 2016 Sep 13;7(37):60206-60217. doi: 10.18632/oncotarget.11115.

10.

The 37/67 kDa laminin receptor (LR) inhibitor, NSC47924, affects 37/67 kDa LR cell surface localization and interaction with the cellular prion protein.

Sarnataro D, Pepe A, Altamura G, De Simone I, Pesapane A, Nitsch L, Montuori N, Lavecchia A, Zurzolo C.

Sci Rep. 2016 Apr 13;6:24457. doi: 10.1038/srep24457.

11.

A Nutritional Approach to the Prevention of Cancer: from Assessment to Personalized Intervention.

Di Furia L, Rusciano MR, Leonardini L, Rossi P, Giammarchi C, Vittori E, Tilocca S, Russo FL, Montuori P, Triassi M, Nardone A, Giaimo MD, Migazzi M, Piffer S, Iaria A, Trapasso A, Firenze A, Cristaudo R, Revello M, Castiglion A, Zagonel V, Iaccarino G, Addis A, Natale L, Di Somma C, Colao A, Perra A, Giova K, Montuori N, Illario M.

Transl Med UniSa. 2016 Jan 31;13:33-41. eCollection 2015 Dec.

12.

Models for preclinical studies in aging-related disorders: One is not for all.

Santulli G, Borras C, Bousquet J, Calzà L, Cano A, Illario M, Franceschi C, Liotta G, Maggio M, Molloy WD, Montuori N, O'Caoimh R, Orfila F, Rauter AP, Santoro A, Iaccarino G.

Transl Med UniSa. 2016 Jan 31;13:4-12. eCollection 2015 Dec.

13.

Biofilms in churches built in grottoes.

Cennamo P, Montuori N, Trojsi G, Fatigati G, Moretti A.

Sci Total Environ. 2016 Feb 1;543(Pt A):727-38. doi: 10.1016/j.scitotenv.2015.11.048. Epub 2015 Dec 7.

PMID:
26618300
14.

Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.

Formisano L, D'Amato V, Servetto A, Brillante S, Raimondo L, Di Mauro C, Marciano R, Orsini RC, Cosconati S, Randazzo A, Parsons SJ, Montuori N, Veneziani BM, De Placido S, Rosa R, Bianco R.

Oncotarget. 2015 Sep 22;6(28):26090-103. doi: 10.18632/oncotarget.4636.

15.

FPRs: linking innate immune system and fibrosis.

Rossi FW, Montuori N.

Oncotarget. 2015 Aug 7;6(22):18736-7. No abstract available.

16.

Urokinase receptor and CXCR4 are regulated by common microRNAs in leukaemia cells.

Alfano D, Gorrasi A, Li Santi A, Ricci P, Montuori N, Selleri C, Ragno P.

J Cell Mol Med. 2015 Sep;19(9):2262-72. doi: 10.1111/jcmm.12617. Epub 2015 Jun 16.

17.

Discovery of new small molecules inhibiting 67 kDa laminin receptor interaction with laminin and cancer cell invasion.

Pesapane A, Di Giovanni C, Rossi FW, Alfano D, Formisano L, Ragno P, Selleri C, Montuori N, Lavecchia A.

Oncotarget. 2015 Jul 20;6(20):18116-33.

18.

Upregulation of the N-formyl Peptide receptors in scleroderma fibroblasts fosters the switch to myofibroblasts.

Rossi FW, Napolitano F, Pesapane A, Mascolo M, Staibano S, Matucci-Cerinic M, Guiducci S, Ragno P, di Spigna G, Postiglione L, Marone G, Montuori N, de Paulis A.

J Immunol. 2015 Jun 1;194(11):5161-73. doi: 10.4049/jimmunol.1402819. Epub 2015 Apr 27.

19.

Urokinase receptor promotes ovarian cancer cell dissemination through its 84-95 sequence.

Bifulco K, Votta G, Ingangi V, Di Carluccio G, Rea D, Losito S, Montuori N, Ragno P, Stoppelli MP, Arra C, Carriero MV.

Oncotarget. 2014 Jun 30;5(12):4154-69.

20.

Novel therapeutic targets in metabolic disorders: from the bench to the bedside.

Illario M, Di Somma C, Iaccarino G, Campiglia P, Sankar U, Montuori N.

ScientificWorldJournal. 2014;2014:365974. doi: 10.1155/2014/365974. Epub 2014 May 13. No abstract available.

21.

Immunological derangement in hypocellular myelodysplastic syndromes.

Serio B, Risitano A, Giudice V, Montuori N, Selleri C.

Transl Med UniSa. 2014 Feb 4;8:31-42. eCollection 2014 Jan.

22.

The urokinase receptor takes control of cell migration by recruiting integrins and FPR1 on the cell surface.

Gorrasi A, Li Santi A, Amodio G, Alfano D, Remondelli P, Montuori N, Ragno P.

PLoS One. 2014 Jan 21;9(1):e86352. doi: 10.1371/journal.pone.0086352. eCollection 2014.

23.

OPSI threat in hematological patients.

Serio B, Pezzullo L, Giudice V, Fontana R, Annunziata S, Ferrara I, Rosamilio R, De Luca C, Rocco M, Montuori N, Selleri C.

Transl Med UniSa. 2013 May 6;6:2-10. eCollection 2013.

24.

Role of uPA/uPAR in the modulation of angiogenesis.

Montuori N, Ragno P.

Chem Immunol Allergy. 2014;99:105-22. doi: 10.1159/000353310. Epub 2013 Oct 17. Review.

PMID:
24217605
25.

Accelerated bone mass senescence after hematopoietic stem cell transplantation.

Serio B, Pezzullo L, Fontana R, Annunziata S, Rosamilio R, Sessa M, Giudice V, Ferrara I, Rocco M, De Rosa G, Ricci P, Tauchmanovà L, Montuori N, Selleri C.

Transl Med UniSa. 2013 Jan 4;5:7-13. Print 2013 Jan.

26.

Discovery of new small molecules targeting the vitronectin-binding site of the urokinase receptor that block cancer cell invasion.

Rea VE, Lavecchia A, Di Giovanni C, Rossi FW, Gorrasi A, Pesapane A, de Paulis A, Ragno P, Montuori N.

Mol Cancer Ther. 2013 Aug;12(8):1402-16. doi: 10.1158/1535-7163.MCT-12-1249. Epub 2013 May 22.

27.

uPAR regulates pericellular proteolysis through a mechanism involving integrins and fMLF-receptors.

Montuori N, Cosimato V, Rinaldi L, Rea VE, Alfano D, Ragno P.

Thromb Haemost. 2013 Feb;109(2):309-18. doi: 10.1160/TH12-08-0546. Epub 2012 Dec 13.

PMID:
23238745
28.

New insights into biological targets and therapeutic management of infectious diseases.

Selleri C, Zeppa P, Montuori N, Esposito S.

Infez Med. 2012;20 Suppl 2:5-7. No abstract available.

29.

Low-dose valgancyclovir as cytomegalovirus reactivation prophylaxis in allogeneic haematopoietic stem cell transplantation.

Serio B, Rosamilio R, Giudice V, Pepe S, Zeppa P, Esposiito S, Pezzullo L, Rocco M, Montuori N, Selleri C.

Infez Med. 2012;20 Suppl 2:26-34.

30.

Hp(2-20) peptide of Helicobacter pylori and the innate immune receptors: specific role(s) of the formyl peptide receptors.

Rossi FW, Prevete N, Montuori N, Ragno P, Selleri C, Marone G, de Paulis A.

Infez Med. 2012;20 Suppl 2:19-25.

31.

The urokinase-receptor in infectious diseases.

Montuori N, Selleri C, Ragno P.

Infez Med. 2012;20 Suppl 2:13-8. Review.

32.

67 kDa laminin receptor: structure, function and role in cancer and infection.

Rea VE, Rossi FW, De Paulis A, Ragno P, Selleri C, Montuori N.

Infez Med. 2012;20 Suppl 2:8-12. Review.

33.

Discovery of new inhibitors of Cdc25B dual specificity phosphatases by structure-based virtual screening.

Lavecchia A, Di Giovanni C, Pesapane A, Montuori N, Ragno P, Martucci NM, Masullo M, De Vendittis E, Novellino E.

J Med Chem. 2012 May 10;55(9):4142-58. doi: 10.1021/jm201624h. Epub 2012 May 1.

PMID:
22524450
34.

PED/PEA-15 interacts with the 67 kD laminin receptor and regulates cell adhesion, migration, proliferation and apoptosis.

Formisano P, Ragno P, Pesapane A, Alfano D, Alberobello AT, Rea VE, Giusto R, Rossi FW, Beguinot F, Rossi G, Montuori N.

J Cell Mol Med. 2012 Jul;16(7):1435-46. doi: 10.1111/j.1582-4934.2011.01411.x.

35.

The cross-talk between the urokinase receptor and fMLP receptors regulates the activity of the CXCR4 chemokine receptor.

Montuori N, Bifulco K, Carriero MV, La Penna C, Visconte V, Alfano D, Pesapane A, Rossi FW, Salzano S, Rossi G, Ragno P.

Cell Mol Life Sci. 2011 Jul;68(14):2453-67. doi: 10.1007/s00018-010-0564-7. Epub 2010 Oct 24.

PMID:
20972812
36.

The plasminogen activator system in fibroblasts from systemic sclerosis.

Postiglione L, Montuori N, Riccio A, Di Spigna G, Salzano S, Rossi G, Ragno P.

Int J Immunopathol Pharmacol. 2010 Jul-Sep;23(3):891-900.

PMID:
20943061
37.

Helicobacter pylori Hp(2-20) promotes migration and proliferation of gastric epithelial cells by interacting with formyl peptide receptors in vitro and accelerates gastric mucosal healing in vivo.

de Paulis A, Prevete N, Rossi FW, Rivellese F, Salerno F, Delfino G, Liccardo B, Avilla E, Montuori N, Mascolo M, Staibano S, Melillo RM, D'Argenio G, Ricci V, Romano M, Marone G.

J Immunol. 2009 Sep 15;183(6):3761-9. doi: 10.4049/jimmunol.0900863. Epub 2009 Aug 19.

38.

Multiple activities of a multifaceted receptor: roles of cleaved and soluble uPAR.

Montuori N, Ragno P.

Front Biosci (Landmark Ed). 2009 Jan 1;14:2494-503. Review.

PMID:
19273214
39.

PED is overexpressed and mediates TRAIL resistance in human non-small cell lung cancer.

Zanca C, Garofalo M, Quintavalle C, Romano G, Acunzo M, Ragno P, Montuori N, Incoronato M, Tornillo L, Baumhoer D, Briguori C, Terracciano L, Condorelli G.

J Cell Mol Med. 2008 Dec;12(6A):2416-26. doi: 10.1111/j.1582-4934.2008.00283.x. Epub 2008 Feb 15.

40.

In vivo activity of the cleaved form of soluble urokinase receptor: a new hematopoietic stem/progenitor cell mobilizer.

Selleri C, Montuori N, Ricci P, Visconte V, Baiano A, Carriero MV, Rotoli B, Rossi G, Ragno P.

Cancer Res. 2006 Nov 15;66(22):10885-90.

41.

Expression and functions of the vascular endothelial growth factors and their receptors in human basophils.

de Paulis A, Prevete N, Fiorentino I, Rossi FW, Staibano S, Montuori N, Ragno P, Longobardi A, Liccardo B, Genovese A, Ribatti D, Walls AF, Marone G.

J Immunol. 2006 Nov 15;177(10):7322-31.

42.

The metastasis-associated 67-kDa laminin receptor is involved in G-CSF-induced hematopoietic stem cell mobilization.

Selleri C, Ragno P, Ricci P, Visconte V, Scarpato N, Carriero MV, Rotoli B, Rossi G, Montuori N.

Blood. 2006 Oct 1;108(7):2476-84. Epub 2006 Jun 20.

43.

Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules?

Montuori N, Visconte V, Rossi G, Ragno P.

Thromb Haemost. 2005 Feb;93(2):192-8. Review.

PMID:
15711732
44.

Urokinase induces basophil chemotaxis through a urokinase receptor epitope that is an endogenous ligand for formyl peptide receptor-like 1 and -like 2.

de Paulis A, Montuori N, Prevete N, Fiorentino I, Rossi FW, Visconte V, Rossi G, Marone G, Ragno P.

J Immunol. 2004 Nov 1;173(9):5739-48.

45.

Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization.

Selleri C, Montuori N, Ricci P, Visconte V, Carriero MV, Sidenius N, Serio B, Blasi F, Rotoli B, Rossi G, Ragno P.

Blood. 2005 Mar 1;105(5):2198-205. Epub 2004 Oct 19.

46.

The RHL-1 subunit of the asialoglycoprotein receptor of thyroid cells: cellular localization and its role in thyroglobulin endocytosis.

Pacifico F, Montuori N, Mellone S, Liguoro D, Ulianich L, Caleo A, Troncone G, Kohn LD, Di Jeso B, Consiglio E.

Mol Cell Endocrinol. 2003 Oct 31;208(1-2):51-9.

PMID:
14580721
47.

Involvement of nitric oxide in farnesyltransferase inhibitor-mediated apoptosis in chronic myeloid leukemia cells.

Selleri C, Maciejewski JP, Montuori N, Ricci P, Visconte V, Serio B, Luciano L, Rotoli B.

Blood. 2003 Aug 15;102(4):1490-8. Epub 2003 Apr 24.

48.

Urokinase-mediated posttranscriptional regulation of urokinase-receptor expression in non small cell lung carcinoma.

Montuori N, Mattiello A, Mancini A, Taglialatela P, Caputi M, Rossi G, Ragno P.

Int J Cancer. 2003 Jun 20;105(3):353-60.

49.

The cleavage of the urokinase receptor regulates its multiple functions.

Montuori N, Carriero MV, Salzano S, Rossi G, Ragno P.

J Biol Chem. 2002 Dec 6;277(49):46932-9. Epub 2002 Sep 23.

50.

Post-transcriptional regulation of gene expression in the plasminogen activation system.

Montuori N, Rossi G, Ragno P.

Biol Chem. 2002 Jan;383(1):47-53. Review.

PMID:
11928821

Supplemental Content

Loading ...
Support Center